$23.50
In stock
Guaranteed refund or reship if you haven't received your order
Secure and encrypted payment processing
We ship to over 40 countries including the USA, UK, Europe, Australia and Japan

Pharmacological properties

Hyporamine, a dry purified extract from the leaves of buckthorn buckthorn (hippophae rhamnoides l.), Is a polyphenolic complex of haloellagotanins, the biologically active components of which are hydrolyzed tannins, which have common structural elements in the form of glucose halal and hexahydroxyphenol residues.

Hyporamine exhibits high antiviral activity against different strains of influenza A and B viruses, adenoviruses, paramyxoviruses, herpes simplex viruses, herpes zoster, cytomegalovirus (CMV), and respiratory syncytial virus (PC virus). The inhibitory effect of the drug on the reproduction of viruses is manifested in the early stages of their development. One of the mechanisms of action of the drug is the inhibitory effect on viral neuraminidase.

Hyporamine induces the production of interferon in blood cells in vitro and increases the content of interferon in the blood of patients.

The in vitro preparation also has a moderate antimicrobial effect with respect to gram-positive (Staphylococcus aureus) and gram-negative bacteria (Escherichia coli, Proteus vulgaris, Pseudomonas aeruginosa), tuberculous mycobacteria (Mycobacterium tuberculosis), candida (Candida albicoricum fungi (some) mycelis).

Indications

As a therapeutic and prophylactic agent for influenza (a and b), parainfluenza, pc-virus, adenovirus and other acute respiratory viral infections; tonsillitis on the background of Orvi (complex therapy); in acute and relapsing forms of herpes simplex of extragenital and genital localization, with herpes zoster, chickenpox and CMV infection.

Application

The drug is taken orally.

Treatment. 1 tablet is kept in the mouth until completely resorbed. Adults and children over 12 years of age are prescribed 1 tablet 4-6 times a day, children aged 6-12 years - 1 tablet 3-4 times a day, children 3-6 years old - ½ tablets 2-4 times per day.

Duration of use - from 3 days to 3 weeks, depending on the nosological form of the disease.

If you take Erebra immediately after the first symptoms of acute respiratory viral infections and influenza, it is enough to take 7 days, if you start after 2–3 days from the onset of the disease, the duration of administration is 14 days, with the development of complications and for the purpose of prevention, the use of the drug should be extended to 21 of the day.

In case of chickenpox, herpes zoster, herpesvirus and CMV infection, the duration of use depends on the severity of the process and is 3–10 days for mild forms of the disease. In severe and recurrent forms of the disease, the minimum course of treatment is 2-3 weeks. Repeated courses of treatment are advisable.

For prophylaxis during a flu outbreak, the drug is taken according to age dosing up to 3 weeks.

Contraindications

Hypersensitivity to the components of the drug. sucrose / isomaltase deficiency, fructose intolerance, glucose-galactose malabsorption.

Side effects

Allergic reactions are possible.

If any adverse reactions develop, discontinue treatment and consult a doctor.

special instructions

It is necessary to appoint as soon as possible in the disease.

Used with caution in diabetes.

1 tablet of the drug contains 0.5539 g of carbohydrates, which corresponds to 0.046 XE. Patients with diabetes should take the drug after consulting a doctor.

Use during pregnancy and lactation. Safety and effectiveness have not been established, therefore, do not apply.

Children. The drug is used in children aged 3 years.

The ability to influence the reaction rate when driving vehicles or working with other mechanisms. Does not affect.

Interactions

It is possible to use the drug in combination with other drugs (antimicrobial agents, synthetic antiviral agents, agents for symptomatic therapy).

Overdose

To date, cases of drug overdose have not been reported.

With prolonged use in doses that exceed those specified in the instructions, an increase in blood coagulation is possible.

The treatment is symptomatic.

Storage conditions

In the original packaging at a temperature not exceeding 25 ° C.

Tags: Orebra® [Hyporamine]